Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin

Thrombosis and Haemostasis

Volumn 93, Issue 5, 2005, Pages 1001-1003

  Miesbach, Wolfgang ^a   Boehm, Martina ^a   Scharrer, Inge ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD CLOTTING INHIBITOR; CILASTATIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; FRESH FROZEN PLASMA; IMIPENEM; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; STEROID; WARFARIN;

AGED; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BRAIN HEMORRHAGE; CASE REPORT; ERYTHROCYTE TRANSFUSION; FEMALE; HEADACHE; HEMATOMA; HUMAN; OTITIS MEDIA; PLASMAPHERESIS; PRIORITY JOURNAL; SIDE EFFECT; STOMACH ULCER; URINARY TRACT INFECTION;

EID: 18844402183     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616574     Document Type: Article

References (22)

1. Dardik R, Loscalzo J, Eskaraev R, et al. Molecular mechanisms underlying the proangiogenic effect of factor XIII. Arterioscler Thromb Vasc Biol 2005; 25: 526-32.
2. Anwar R, Minford A, Gallivan L, et al. Delayed umbilical bleeding - a presenting feature for factor XIII deficiency: clinical features, genetics, and management. Pediatrics 2002; 109: E32.
3. Board PG, Losokowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency: Blood Rev 1993; 7: 229-42.
4. Born P, Lippl F, Ulm K, et al. Reduced levels of coagulation factor XIII in patients with advanced tumor disease. Hepatogastroenterology 2000; 47: 194-8.
5. Loswsky MS, Miloszowsky KJ. Factor XIII. Br J Haematol 1977; 37: 1-5.
6. Board PG, Losowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency. Blood Rev 1993; 7: 229-42.
7. Seitz R, Duckert F, Lopaciuk MD. ETRO working party on factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Semin Thromb Haemost 1996; 22: 415-8.
8. Jennings I, Kitchen S, Woods AL, et al. Problems realting to the laboratory diagnosis of factor XIII deficiency: a NEQAS study. J Thromb Haemost 2003; 1: 2603-8.
9. Kaspar CK. Laboratory tests for factor VIII inhibitors, their variation, significance and interpretation. Blood Coagul Fibrinolysis 1991; 2: 7-10.
10. Ahmad F, Solymoss S, Poon MC, et al. Characterization of an acquired IgG inhibitor of coagulation factor XIII in a patient with systemic lupus erythematosus. Br J Haematol 1996; 93: 700-3.
11. Lorand L, Velasco PT, Hill JM, et al. Intracranial hemorrhage in systemic lupus erythematosus associated with an autoantibody against factor XIII. Thromb Haemost 2002; 88: 919-23.
12. McDevitt NB, McDonagh J, Taylor HL, et al. An acquired inhibitor to factor XIII. Arch Intern Med 1972; 130: 772-7.
13. McDonagh J. Structure and function of factor XIII. In: Colman RW, Hirsh J, Marder VJ, Saltzman EW, eds. Hemostasis and Thrombosis: Basic principles and clinical practice, 3th edn. Philadelphia, PA:JB Lippncott Co., 1994: 301.
14. Nijenhuis AVM, van Bergeijk L, Huijgens PC, et al. Acquired factor XIII deficiency due to an inhibitor: a case report and review of the literature. Haematologica 2004; 89: 14-9.
15. van Beek EJ, Peters M, ten Cate JW. Factor VIII inhibitor associated with ciprofloxacin. Thromb Haemost 1993; 69: 403.
16. Miesbach W, Voigt J, Peetz D, et al. Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin. Med Klin 2003; 98: 339-43.
17. Daly HM, Carson PJ, Smith JK. Intracerebral hemorrhage due to acquired factor XIII inhibitor - successful response to factor XIII concentrate. Blood Coagul Fibrinolysis 1991; 2: 507-14.
18. Tosetto A, Rodeghiero F, Gatto E, et al. An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide. Am J Hematol 1995; 48: 34-9.
19. Schwartz RS, Gabriel DA, Aledort LM, et al. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitor with high-dose intravenous gammaglobin. Blood 1995; 86: 797-804.
20. Stasi R, Brunetti M, Stipa E, et al. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
21. Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-7.
22. Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358: 1511-3.